Bioarray Therapeutics is a technology company.
Bioarray Therapeutics has raised $4.0M across 1 funding round.
Bioarray Therapeutics has raised $4.0M in total across 1 funding round.
Bioarray Therapeutics has raised $4.0M in total across 1 funding round.
Bioarray Therapeutics's investors include Connecticut Innovations.
BIOARRAY Therapeutics, Inc. (also referenced as BIOARRAY Genetics, Inc.) is a clinical-stage biotechnology company developing RNA-based molecular diagnostics to predict cancer patients' responses to treatments, primarily focusing on breast cancer.[1][3][4] It builds predictive tests like BA100, an RNA-based assay that identifies responders and non-responders to standard chemotherapy in stage I-III breast cancer patients, serving oncologists, patients, and healthcare systems to reduce ineffective treatments, cut costs (e.g., $2.59B annual U.S. spend), and improve outcomes by up to 68% response increase.[1] The company addresses a key unmet need in precision oncology, with a U.S. market opportunity of $542M, operating from Connecticut as a prototype-ready C-corp founded in 2009 with a small team of about 5 employees.[1]
BIOARRAY was founded in December 2009 by Marcia Fournier, PhD in molecular biology from Federal University of Rio de Janeiro, who serves as CEO and board director.[1] Inspired by precision medicine, Fournier brought over 15 years of expertise in oncology, drug discovery, biomarkers, and clinical diagnostics from leading institutions like GlaxoSmithKline, UC Berkeley, and Dana-Farber Cancer Institute.[1] The idea emerged from gaps in cancer evaluation, leading to proprietary panels of over 300 genes and algorithms for predictive tests; early traction included prototype readiness for BA100 and seed funding from Avon Foundation for Women and Connecticut Innovations.[1]
BIOARRAY rides the precision oncology wave, leveraging RNA diagnostics and next-generation sequencing amid rising demand for personalized cancer care, where market forces like escalating treatment costs ($2.59B/year for ineffective chemo) and regulatory pushes for companion diagnostics favor its timing.[1][5] It influences the ecosystem by enabling data-driven decisions that cut waste and boost efficacy, aligning with biotech trends in molecular profiling and ctDNA detection, while small-team agility allows focus on high-impact niches like breast cancer amid broader NGS adoption.[1][3][5]
BIOARRAY is poised for growth through BA100 commercialization and expansion into other cancers via its gene panel, potentially capturing its $542M market as precision diagnostics scale.[1] Trends like AI-enhanced algorithms and liquid biopsies will shape its path, evolving its influence from niche predictor to broader oncology platform—watch for partnerships or trials to accelerate adoption, building on its precision medicine foundation.[1][3]
Bioarray Therapeutics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series B in October 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2017 | $4.0M Series B | Connecticut Innovations |